Xu YK - Search Results

1

Optimal virtual monochromatic images for assessing metastatic lateral cervical lymph nodes in patients with papillary thyroid carcinoma using dual‑layer spectral detector computed tomography.

Xu YK, Chai TT, Wang JW, Su GY, Si Y, Wu FY, Xu XQ. Xu YK, et al. Eur J Radiol. 2024 Sep;178:111623. doi: 10.1016/j.ejrad.2024.111623. Epub 2024 Jul 14. Eur J Radiol. 2024. PMID: 39018649

2

Added value of arterial enhancement fraction derived from dual-energy computed tomography for preoperative diagnosis of cervical lymph node metastasis in papillary thyroid cancer: initial results.

Zhou Y, Xu YK, Geng D, Wang JW, Chen XB, Si Y, Shen MP, Su GY, Xu XQ, Wu FY. Zhou Y, et al. Among authors: xu yk, xu xq. Eur Radiol. 2024 Feb;34(2):1292-1301. doi: 10.1007/s00330-023-10109-0. Epub 2023 Aug 17. Eur Radiol. 2024. PMID: 37589903

3

Texture analysis of diffusion kurtosis imaging for differentiating malignant from benign sinonasal lesions: added value to conventional imaging features.

Su GY, Xu YK, Liu J, Hu H, Lu MP, Yin M, Xu XQ, Wu FY. Su GY, et al. Among authors: xu yk, xu xq. Br J Radiol. 2023 Mar 1;96(1144):20220806. doi: 10.1259/bjr.20220806. Epub 2023 Feb 13. Br J Radiol. 2023. PMID: 36715108 Free PMC article.

4

CKLF as a Prognostic Biomarker and Its Association with Immune Infiltration in Hepatocellular Carcinoma.

Li D, Huang S, Luo C, Xu Y, Fu S, Liu K, Wu J. Li D, et al. Curr Oncol. 2023 Feb 22;30(3):2653-2672. doi: 10.3390/curroncol30030202. Curr Oncol. 2023. PMID: 36975415 Free PMC article.

5

MicroRNA 211-5p inhibits cancer cell proliferation and migration in pancreatic cancer by targeting BMP2.

Li D, Luo C, Deng J, Xu Y, Fu S, Liu K, Wu J. Li D, et al. Aging (Albany NY). 2023 Dec 6;15(23):14411-14421. doi: 10.18632/aging.205320. Epub 2023 Dec 6. Aging (Albany NY). 2023. PMID: 38059889 Free PMC article.

6

Diagnostic Accuracy of Artificial Intelligence Based on Imaging Data for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Zhang J, Huang S, Xu Y, Wu J. Zhang J, et al. Front Oncol. 2022 Feb 24;12:763842. doi: 10.3389/fonc.2022.763842. eCollection 2022. Front Oncol. 2022. PMID: 35280776 Free PMC article.

7

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib.

Xu Y, Fu S, Shang K, Zeng J, Mao Y. Xu Y, et al. Front Oncol. 2022 Sep 13;12:958869. doi: 10.3389/fonc.2022.958869. eCollection 2022. Front Oncol. 2022. PMID: 36176403 Free PMC article.

8

Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.

Shang K, Huang H, Xu Y, Liu Y, Lu Z, Chen L. Shang K, et al. BMC Cancer. 2022 Dec 12;22(1):1295. doi: 10.1186/s12885-022-10391-z. BMC Cancer. 2022. PMID: 36503478 Free PMC article.

9

[Spatial-temporal distribution of newly reported HIV/AIDS cases in Henan Province, 1995-2020].

Liang Y, Xu YK, Fan PY, Nie YG, Geng J, Shi JC, Zhang GL, Zhao DY. Liang Y, et al. Among authors: xu yk. Zhonghua Liu Xing Bing Xue Za Zhi. 2024 Dec 10;45(12):1685-1692. doi: 10.3760/cma.j.cn112338-20240618-00359. Zhonghua Liu Xing Bing Xue Za Zhi. 2024. PMID: 39681426 Chinese.

10

Advancing EGFR mutation subtypes prediction in NSCLC by combining 3D pretrained ConvNeXt, radiomics, and clinical features.

Hao P, Yu Y, Huang CT, Zhou F, Xu YK, Yang J, Xu J. Hao P, et al. Among authors: xu yk. Front Oncol. 2024 Nov 15;14:1464555. doi: 10.3389/fonc.2024.1464555. eCollection 2024. Front Oncol. 2024. PMID: 39619439 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

215 results

Search Page

Filters